Literature DB >> 9855325

Retrospective and prospective analyses of the treatment of overanticoagulated patients.

T M Duong1, B K Plowman, A P Morreale, K Janetzky.   

Abstract

STUDY
OBJECTIVE: To compare withholding warfarin therapy with low-dose (2.5 mg) oral vitamin K therapy in excessively anticoagulated patients without bleeding complications.
DESIGN: Prospective and retrospective studies.
SETTING: Anticoagulation clinic at a Veterans Affairs institution. PATIENTS: Twenty-eight men were matched according to initial international normalized ratio (INR) and INR goal ranges.
INTERVENTIONS: The retrospective arm of the study consisted of chart reviews of overanticoagulated patients whose warfarin doses were held until therapeutic INR values were reached. The prospective arm included overanticoagulated patients who were administered a single 2.5-mg dose of oral vitamin K.
MEASUREMENTS AND MAIN RESULTS: Mean days to therapeutic INR values were 2.3+/-0.6 and 1.4+/-0.6 (p=0.001), and mean reduction in INR 1 day after treatment intervention was 1.32+/-0.79 and 3.46+/-1.31 (p<001) U for the withholding and vitamin K groups, respectively.
CONCLUSION: Compared with withholding the warfarin dose, administration of 2.5 mg of oral vitamin K to excessively anticoagulated patients receiving warfarin significantly reduced the time required to reach a therapeutic INR as well as final INR.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855325

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  6 in total

1.  Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study.

Authors:  Nita A Limdi; Thomas D Nolin; Sarah L Booth; Amanda Centi; Marisa B Marques; Michael R Crowley; Michael Allon; T Mark Beasley
Journal:  Am J Kidney Dis       Date:  2014-11-25       Impact factor: 8.860

Review 2.  Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient.

Authors:  Michael Makris; Joost J van Veen; Rhona Maclean
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

Review 3.  Reversal of oral anticoagulation.

Authors:  Jonathan L Thigpen; Nita A Limdi
Journal:  Pharmacotherapy       Date:  2013-04-18       Impact factor: 4.705

Review 4.  Vitamin K for the treatment of asymptomatic coagulopathy associated with oral anticoagulant therapy.

Authors:  Mark A Crowther; Sarah Wilson
Journal:  J Thromb Thrombolysis       Date:  2003 Aug-Oct       Impact factor: 2.300

Review 5.  Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review.

Authors:  Sarah E Wilson; Henry G Watson; Mark A Crowther
Journal:  CMAJ       Date:  2004-03-02       Impact factor: 8.262

6.  A retrospective evaluation of the management of excessive anticoagulation in an established clinical pharmacy anticoagulation service compared to traditional care.

Authors:  Daniel M Witt; Tammy L Humphries
Journal:  J Thromb Thrombolysis       Date:  2003-04       Impact factor: 2.300

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.